Hamada S Abulkhair

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 28

Top Venues

Archiv der Pharmazie

Future medicinal chemistry

Journal of biomolecular structure & dynamics

Pharmaceuticals (Basel, Switzerland)

Faculty of Pharmacy, Al-Azhar Universitytry

Faculty of Pharmacy, Al-Azhar University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Faculty of Pharmacy, Al-Azhar Universitytry

Egypt

Lecturer :: Pharmaceutical Organic Chemispartment

Education History

Faculty of Pharmacy, Al-Azhar University May 22 2010

Egypt

PHD :: Pharmaceutical Organic Chemistrty Department

Publications

Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed Ali Al-Karmalawy, Ebtehal M Husseiny
Novel benzochromenes: design, synthesis, cytotoxicity, molecular docking and mechanistic investigations. Future medicinal chemistry (2024)
Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed Ali Al-Karmalawy, Ebtehal M Husseiny
Novel benzochromenes: design, synthesis, cytotoxicity, molecular docking and mechanistic investigations. Future medicinal chemistry 16 (2) (2024)
Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed Ali Al-Karmalawy, Ebtehal M Husseiny
Novel benzochromenes: design, synthesis, cytotoxicity, molecular docking and mechanistic investigations. Future medicinal chemistry 16 (2) (2024)
Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed Ali Al-Karmalawy, Ebtehal M Husseiny
Novel benzochromenes: design, synthesis, cytotoxicity, molecular docking and mechanistic investigations. Future medicinal chemistry 16 (2) (2024)
Arafa Musa, Saleh K Ihmaid, David L Hughes, Musa A Said, Hamada S Abulkhair, Ahmed H El-Ghorab, Mohamed Abdelwahab Abdelgawad, Khaled Shalaby, Mohamed E Shaker, Khalid Saad Alharbi, Nasser Hadal Alotaibi, Deborah L Kays, Laurence J Taylor, Della Grace Thomas Parambi, Sami I Alzarea, Ahmed Ali Al-Karmalawy, Hany E A Ahmed, Ahmed M El-Agrody
The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro , and in silico mechanistic investigations. Journal of biomolecular structure & dynamics (2023)
Ebtehal M Husseiny, Hamada S Abulkhair, Sanadelaslam Sa El-Hddad, Nada Osama, Mona S El-Zoghbi
Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future medicinal chemistry (2023)
Arafa Musa, Hamada S Abulkhair, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed Abdelwahab Abdelgawad, Khaled Shalaby, Ahmed H El-Ghorab, Mohamed Reda Aouad
Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Samar A El-Kalyoubi, Samar S Elbaramawi, Ahmed G Eissa, Essam Al Ageeli, Yahya Hasan Hobani, Aya Ali El-Sharkawy, Hossam Taha Mohamed, Ahmed Ali Al-Karmalawy, Hamada S Abulkhair
Design and synthesis of novel uracil-linked Schiff bases as dual histone deacetylase type II/topoisomerase type I inhibitors with apoptotic potential. Future medicinal chemistry (2023)
Arafa Musa, Hamada S Abulkhair, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed Abdelwahab Abdelgawad, Khaled Shalaby, Ahmed H El-Ghorab, Mohamed Reda Aouad
Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Arafa Musa, Hamada S Abulkhair, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed Abdelwahab Abdelgawad, Khaled Shalaby, Ahmed H El-Ghorab, Mohamed Reda Aouad
Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Maan T Khayat, Hany E A Ahmed, Abdelsattar Mansour Omar Ebeid, Yosra A Muhammad, Khadijah A Mohammad, Azizah M Malebari, Ahdab N Khayyat, Ahmed H Halawa, Hamada S Abulkhair, Ahmed Ali Al-Karmalawy, Mohammed Almaghrabi, Majed Alharbi, Anfal S Aljahdali, Ahmed M El-Agrody
A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses. Journal of biomolecular structure & dynamics (2023)
Khaled El-Adl, Helmy M Sakr, Reda G Yousef, Ahmed B M Mehany, Hamada S Abulkhair, Ibrahim H Eissa
New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Archiv der Pharmazie 355 (7) (2022)
Ateyatallah Aljuhani, Hany E A Ahmed, Saleh K Ihmaid, Abdelsattar M Omar, Sultan S Althagfan, Yaser M Alahmadi, Iqrar Ahmad, Harun Patel, Sahar Ahmed, Mohannad A Almikhlafi, Ahmed M El-Agrody, Mohamed F Zayed, Safaa Abdulrahman Turkistani, Shorouk H Abulkhair, Mohammed Almaghrabi, Samir A Salama, Ahmed Ali Al-Karmalawy, Hamada S Abulkhair
In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-M Pro inhibitors. RSC advances 12 (41) (2022)
Mohamed M Hammoud, Muhammad Khattab, Marwa Abdel-Motaal, Johan Van der Eycken, Radwan Alnajjar, Hamada S Abulkhair, Ahmed Ali Al-Karmalawy
Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity. Journal of biomolecular structure & dynamics (2022)
Ahmed A Zaki, Mohamed Mohamed Yousri Kaddah, Hamada S Abulkhair, Ahmed Ashour
Unravelling the antifungal and antiprotozoal activities and LC-MS/MS quantification of steroidal saponins isolated from Panicum turgidum . RSC advances 12 (5) (2022)
Ayman Abo Elmaaty, Mohammed I A Hamed, Muhammad I Ismail, Eslam B Elkaeed, Hamada S Abulkhair, Muhammad Khattab, Ahmed Ali Al-Karmalawy
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Molecules (Basel, Switzerland) 26 (12) (2021)
Hamada S Abulkhair, Salwa Elmeligie, Adel Ghiaty, Ahmed El-Morsy, Ashraf H Bayoumi, Hany E A Ahmed, Khaled El-Adl, Mohamed F Zayed, Memy H Hassan, Eman N Akl, Mona S El-Zoghbi
In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors. Archiv der Pharmazie 354 (5) (2021)
Fathalla Khedr, Mohamed-Kamal Ibrahim, Ibrahim H Eissa, Hamada S Abulkhair, Khaled El-Adl
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Archiv der Pharmazie 354 (11) (2021)
Khaled El-Adl, Mohamed K Ibrahim, Fathalla Khedr, Hamada S Abulkhair, Ibrahim H Eissa
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Archiv der Pharmazie (2021)
Mohammed I A Hamed, Khaled M Darwish, Raya Soltane, Amani Chrouda, Ahmed Mostafa, Noura M Abo Shama, Sameh S Elhady, Hamada S Abulkhair, Ahmed E Khodir, Ayman Abo Elmaaty, Ahmed Ali Al-Karmalawy
β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico , in vitro , and SAR studies for lead optimization. RSC advances 11 (56) (2021)
Ahmed A Gaber, Ahmed M El-Morsy, Farag F Sherbiny, Ashraf H Bayoumi, Kamal M El-Gamal, Khaled El-Adl, Ahmed Ali Al-Karmalawy, Rogy R Ezz Eldin, Marwa A Saleh, Hamada S Abulkhair
Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Archiv der Pharmazie (2021)
Khaled El-Adl, Helmy Sakr, Sanadelaslam S A El-Hddad, Abdel-Ghany A El-Helby, Mohamed Nasser, Hamada S Abulkhair
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Archiv der Pharmazie 354 (7) (2021)
Abdallah Turky, Ashraf H Bayoumi, Farag F Sherbiny, Khaled El-Adl, Hamada S Abulkhair
Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies. Molecular diversity 25 (1) (2020)
Mohamed H El-Shershaby, Kamal M El-Gamal, Ashraf H Bayoumi, Khaled El-Adl, Hany E A Ahmed, Hamada S Abulkhair
Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives. Archiv der Pharmazie 354 (2) (2020)
Khaled El-Adl, Mohamed-Kamal Ibrahim, Fathalla Khedr, Hamada S Abulkhair, Ibrahim H Eissa
N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Archiv der Pharmazie 354 (3) (2020)
Hany G Ezzat, Ashraf H Bayoumi, Farag F Sherbiny, Ahmed M El-Morsy, Adel Ghiaty, Mohamed Alswah, Hamada S Abulkhair
Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists. Molecular diversity 25 (1) (2020)
Abdallah Turky, Farag F Sherbiny, Ashraf H Bayoumi, Hany E A Ahmed, Hamada S Abulkhair
Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. Archiv der Pharmazie 353 (12) (2020)
Khaled El-Adl, Abdel-Ghany A El-Helby, Helmy Sakr, Rezk R Ayyad, Hazem A Mahdy, Mohamed Nasser, Hamada S Abulkhair, Sanadelaslam S A El-Hddad
Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Archiv der Pharmazie 354 (2) (2020)

Hamada S Abulkhair.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hamada S Abulkhair